Combination therapy for preservation of beta cell function in Type 1 diabetes: New attitudes and strategies are needed!

Immunology Letters

Volumn 159, Issue 1-2, 2014, Pages 30-35

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antigen treatment; Beta cell regeneration; C peptide; Combination therapies; Immune intervention; Type 1 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; IBUPROFEN; INSULIN; NICOTINAMIDE; VITAMIN D; ANTIDIABETIC AGENT;

CELL FUNCTION; CELL REGENERATION; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MOTIVATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRESERVATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MICE; TREATMENT OUTCOME;

EID: 84896030882     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.02.006     Document Type: Review

References (41)

1. Johnsson S. Retinopathy and nephropathy in diabetes mellitus - a comparison of the effects of two forms of treatment. Diabetes 1960, 9:1-8.
2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1975. Diab Care 1978, 1:168-188.
3. Lauritzen T., Frost-Larsen K., Larsen H.W., Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983, 1:200-204.
4. Dahl-Jørgensen K., Brinchmann-Hansen O., Hanssen K.F., Ganes T., Kierulf P., Smeland E., et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986, 293:1195-1199.
5. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304-309.
6. Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994, 330:15-18.
7. The Diabetes Control Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
8. Haugstvedt A., Wentzel-Larsen T., Rokne B., Graue M. Perceived family burden and emotional distress: similarities and differences between mothers and fathers of children with type 1 diabetes in a population-based study. Pediatr Diab 2011, 12:107-114.
9. Harjutsalo V., Forsblom C., Groop P.H. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. Br Med J 2011, 343:d5364.
10. Phillip M., Battelino T., Atlas E., Kordonouri O., Bratina N., Miller S., et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013, 368:824-833.
11. Elleri D., Allen J.M., Kumareswaran K., Leelarathna L., Nodale M., Caldwell K., et al. Closed-loop basal insulin delivery over 36hours in adolescents with type 1 diabetes: randomized clinical trial. Diab Care 2013, 36:838-844.
12. Madsbad S., Alberti K.G., Binder C., Burrin J.M., Faber O.K., Krarup T., et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979, 2:1257-1259.
13. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diab Care 2003, 26:832-836.
14. Cudworth A.G., Woodrow J.C. Letter HL-A antigens and diabetes mellitus. Lancet 1974, 2:1153.
15. Bottazzo G.F., Florin-Christensen A., Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974, 27892:1279-1283.
16. Sutherland D.E., Sibley R., Xu X.Z., Michael A., Srikanta A.M., Taub F., et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Phys 1984, 97:80-87.
17. Gepts W., Lecompte P.M. The pancreatic islets in diabetes. Am J Med 1981, 70:105-115.
18. Dupré J., Stiller C.R., Gent M., Donner A., von Graffenried B., Heinrichs D., et al. Clinical trials of cyclosporin in IDDM. Diab Care 1988, 11(Suppl. 1):37-44.
19. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346:1692-1698.
20. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
21. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
22. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
23. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
24. Ludvigsson J., Krisky D., Casas R., Battelino T., Castaño L., Greening J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366:433-442.
25. Greenbaum C.J., Harrison L.C. Immunology of Diabetes Society Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003, 52:1059-1065.
26. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Antigen-based therapy with glutamic acid decarboxylase [GAD] vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Type 1 Diabetes TrialNet GAD Study Group. Lancet 2011, 378:319-327.
27. Greenbaum C.J., Beam C.A., Boulware D., Gitelman S.E., Gottlieb P.A., Herold K.C., et al. Type 1 Diabetes TrialNet Study Group Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012, 61:2066-2073.
28. Ludvigsson J., Carlsson A., Deli A., Forsander G., Ivarsson S.A., Kockum I., et al. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diab Res Clin Pract 2013, 100:203-209.
29. Barker A., Lauria A., Schloot N., Hosszufalusi N., Ludvigsson J., Mathieu C., et al. Age-dependent decline of β cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diab Obes Metab 2013, October, [Epub ahead of print]. 10.1111/dom.12216.
30. Hagopian W., Ferry R.J., Sherry N., Carlin D., Bonvini E., Johnson S., et al. Protégé Trial Investigators Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013, 62:3901-3908.
31. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
32. Bizzarri C., Pitocco D., Napoli N., Di Stasio E., Maggi D., Manfrini S., et al. IMDIAB Group. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diab Care 2010, 33:1962-1963.
33. Moran A., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013, 381:1905-1915.
34. Ludvigsson J., Samuelsson U., Johansson C., Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diab Metab Res Rev 2001, 17:131-136.
35. Miani M., Barthson J., Colli M.L., Brozzi F., Cnop M., Eizirik D.L. Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1β-induced apoptosis viaBim/A1 imbalance. Cell Death Dis 2013, 4(July):e701. 10.1038/cddis.2013.236.
36. Ludvigsson J. Is it time to challenge the established theories surrounding type 1 diabetes?. Acta Paediatr 2013, October, [Epub ahead of print]. 10.1111/apa.2.1245.
37. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. Intervention Trial (ENDIT) Group. Lancet 2004, 363:925-931.
38. Ludvigsson J., Chéramy M., Axelsson S., Pihl M., Akerman L. Casas R for the clinical GAD-study group in Sweden. GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30 months. Diab Metab Res Rev 2013, December, [Epub ahead of print]. 10.1002/dmrr.2503.
39. Peters M.J. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study: response to Mastrandrea et al. Diab Care 2009, 32:e153.
40. Tortosa F., Dotta F. Incretin hormones and beta-cell mass expansion: what we know and what is missing?. Arch Physiol Biochem 2013, 119:161-169.
41. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. J Am Med Assoc 2009, 301:1573-1579.